Literature DB >> 12616592

Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability.

Marcin Kruszewski1, Elzbieta Bouzyk, Tomasz Oldak, Krystyna Samochocka, Leon Fuks, Włodzimierz Lewandowski, Izabela Fokt, Waldemar Priebe.   

Abstract

The aim of this work was to test the cytotoxicity of newly synthesized cis-type complexes of platinum(II) and palladium(II) dichloride with methyl 3,4-diamine-2,3,4,6-tetradeoxy-alpha-L-lyxohexopyranoside, [M(C(7)H(16)N(2)O(2))Cl(2)].H(2)O, against two mouse lymphoma cell lines (L5178Y) differing in their double strand breaks and nucleotide excision repair ability. cis- Diaminedichloroplatinum (CDDP) was used as a reference compound. The toxicity of Pt(C(7)H(16)N(2)O(2))Cl(2) appeared to be similar for both cell lines: IC(50) is 8 microM for L5178Y-R cells and 12 microM for L5178Y-S cells, respectively. In contrast, the palladium complex was found to be more toxic for the LY-R cells than for the LY-S cells. The cytotoxicity of both compounds was compared with their ability to induce DNA crosslinks, as measured by the modified comet assay. CDDP caused retardation of the DNA migration induced by 2 Gy of the X-irradiation in a dose-dependent manner. The ability of Pd(C(7)H(16)N(2)O(2))Cl(2) to retard X-ray induced DNA migration was more pronounced than its platinum analogue and CDDP (see Fig. 6). However, this was not reflected in the toxicity of the compound. Such results indicate that these two compounds may cause a different type of DNA damage and/or that the DNA damage caused by the palladium(II) compound was dealt with in a different manner from that induced by the platinum(II) complex. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12616592     DOI: 10.1002/tcm.10046

Source DB:  PubMed          Journal:  Teratog Carcinog Mutagen        ISSN: 0270-3211


  2 in total

1.  Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.

Authors:  Mamoru Tanaka; Hiromi Kataoka; Shigenobu Yano; Hiromi Ohi; Keisuke Kawamoto; Takashi Shibahara; Tsutomu Mizoshita; Yoshinori Mori; Satoshi Tanida; Takeshi Kamiya; Takashi Joh
Journal:  BMC Cancer       Date:  2013-05-14       Impact factor: 4.430

2.  The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells.

Authors:  Jenna Susan Bleloch; André du Toit; Liezl Gibhard; Serah Kimani; Reyna Deeya Ballim; Minkyu Lee; Angelique Blanckenberg; Selwyn Mapolie; Lubbe Wiesner; Ben Loos; Sharon Prince
Journal:  Cell Death Discov       Date:  2019-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.